promo_leaderboard Ad
‹ All stocks
PTGX

Protagonist Therapeutics

PTGX · NASDAQ · Healthcare
$123.54
▼ $1.29 (-1.03%)
$123.54 $123.76 $123.98 $124.20 $123.54 21:34 15:04
Day range
$123.43 – $125.90
Year range
$77.00 – $160.81
Open
$124.65
Previous close
$124.83
Market cap
$8.06B
Volume (24h)
$20.2K
Volume (52w)
$2.49M
Performance
7D
▼ -9.34%
1M
▼ -8.11%
3M
▼ -20.27%
6M
▲ 21.11%
1Y
▲ 45.74%
YTD
▲ 41.71%
3Y
▲ 616.59%
5Y
▲ 239.30%
All-time
▲ 955.90%
Key statistics
P/E ratio
26.17
EPS (TTM)
$4.72
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
65.3M
About Protagonist Therapeutics

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Visit website
Country: United States of America
More in Healthcare